C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter H—Medical DevicesPart 821—Medical Device Tracking RequirementsSubpart A—General Provisions

21 C.F.R. § 821.1 (2026)

Scope

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 cited 2005–2016 5citing cases
At a glance

Courts have cited this section in 5 opinions since 2005.

(a) The regulations in this part implement section 519(e) of the Federal Food, Drug, and Cosmetic Act (the act), which provides that the Food and Drug Administration may require a manufacturer to adopt a method of tracking a class II or class III device, if the device meets one of the following three criteria and FDA issues an order to the manufacturer: the failure of the device would be reasonably likely to have serious adverse health consequences; or the device is intended to be implanted in the human body for more than 1 year; or the device is a life-sustaining or life-supporting device used outside a device user facility. A device that meets one of these criteria and is the subject of an FDA order must comply with this part and is referred to, in this part, as a “tracked device.”

(b) These regulations are intended to ensure that tracked devices can be traced from the device manufacturing facility to the person for whom the device is indicated, that is, the patient. Effective tracking of devices from the manufacturing facility, through the distributor network (including distributors, retailers, rental firms and other commercial enterprises, device user facilities, and licensed practitioners) and, ultimately, to the patient is necessary for the effectiveness of remedies prescribed by the act, such as patient notification (section 518(a) of the act) or device recall (section 518(e) of the act). Although these regulations do not preclude a manufacturer from involving outside organizations in that manufacturer's device tracking effort, the legal responsibility for complying with this part rests with manufacturers who are subject to tracking orders, and that responsibility cannot be altered, modified, or in any way abrogated by contracts or other agreements.

(c) The primary burden for ensuring that the tracking system works rests upon the manufacturer. A manufacturer or any other person, including a distributor, final distributor, or multiple distributor, who distributes a device subject to tracking, who fails to comply with any applicable requirement of section 519(e) of the act or of this part, or any person who causes such failure, misbrands the device within the meaning of section 502(t)(2) of the act and commits a prohibited act within the meaning of sections 301(e) and 301(q)(1)(B) of the act.

(d) Any person subject to this part who permanently discontinues doing business is required to notify FDA at the time the person notifies any government agency, court, or supplier, and provide FDA with a complete set of its tracking records and information. However, if a person ceases distribution of a tracked device but continues to do other business, that person continues to be responsible for compliance with this part unless another person, affirmatively and in writing, assumes responsibility for continuing the tracking of devices previously distributed under this part. Further, if a person subject to this part goes out of business completely, but other persons acquire the right to manufacture or distribute tracked devices, those other persons are deemed to be responsible for continuing the tracking responsibility of the previous person under this part.

[58 FR 43447, Aug. 16, 1993, as amended at 67 FR 5951, Feb. 8, 2002; 73 FR 34860, June 19, 2008]
The 5 cases that cite 21 C.F.R. § 821.1 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENJack McMullen v. Medtronic, Inc., 421 F.3d 482 (7th Cir. 2005).
cites § 821.1 1×cited by 81 cases
Where it cites § 821.1
“Contrary to McMullen’s contention, however, neither of these regulations, considered alone or together, imposed upon Medtronic a duty to issue an additional warning between January and March 2001.”
The case’s holding
A state law duty is preempted when federal law permits a course of conduct but does not make it obligatory.
Later courts cite it for
“where a federal requirement permits a course of conduct and the state makes it obligatory, the state's requirement is in addition to the federal requirement and thus is preempted.” · 9 citing courts
2
GREENLaverty v. Smith & Nephew, Inc., 197 F. Supp. 3d 1026 (N.D. Ill. 2016).
cites § 821.1 1×cited by 13 cases
Where it cites § 821.1
“at 489 (quoting 21 C.F.R. § 821.1 ). The described remedies “give the Secretary of Health and Human Services the discretion to issue or withhold warnings concerning medical devices based on the Secretary’s assessment of the risks, and to issue recall orders” if the Secretary so…”
Later courts cite it for
“accordingly, a court may grant a rule 12(c) motion only where it is clear from the pleadings that the plaintiffs will be unable to maintain their cause of action in light of the facts presented.” · 3 citing courts
3
GREENRollins v. St. Jude Med., 583 F. Supp. 2d 790 (W.D. La. 2008).
cites § 821.1 1×cited by 18 cases
Where it cites § 821.1
“21 C.F.R. § 821.1 (a) and (b) state as follows in pertinent part: (a) The regulations in this part implement section 519(e) of the Federal Food, Drug, and Cosmetic Act (the act), which provides that the Food and Drug Administration may require a manufacturer to adopt a method of…”
Later courts cite it for
“may take judicial notice of and consider the public records of the fda ... without transforming a motion to dismiss into a motion for summary judgment.” · 2 citing courts
4
GREENStevens v. Boston Sci. Corp., 152 F. Supp. 3d 527 (S.D. W. Va. 2016).
cites § 821.1 1×cited by 2 cases
Summary
No passage or summary on file for this case yet.
5
GREENMcMullen, Jack v. Medtronic Inc, No. 04-3678 (7th Cir. Aug. 26, 2005).
cites § 821.1 1×cited by 0 cases
Where it cites § 821.1
“39, which permits manufac- turers to enhance warnings pending approval of a proposed change to an earlier-approved warning. Contrary to McMullen’s contention, however, neither of these regula- tions, considered alone or together, imposed upon Medtronic a duty to issue an…”

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
200520102016

One bar per year. Tallest: 2 cases in 2005. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
7th Cir.2N.D. Ill.1W.D. La.1S.D.W. Va1
By subsection

Courts have not cited this section by subsection, so its cases are not split up here. The Leading cases tab lists the cases that cite it most heavily.

Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com